Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer

This study provides the first direct evidence from ex vivo fresh TIL assays using human NSCLC clinical specimens that amivantamab can activate immune responses. EGFR and MET expression may serve as potential biomarkers for amivantamab-induced immune responses.

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-03-24
DOI
https://doi.org/10.1007/s00262-026-04369-0
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer

Cancer Immunology Immunotherapy
Lung Cancer Treatments and Mutations
article

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer

article en

Abstract

This study provides the first direct evidence from ex vivo fresh TIL assays using human NSCLC clinical specimens that amivantamab can activate immune responses. EGFR and MET expression may serve as potential biomarkers for amivantamab-induced immune responses.

Cancer Immunology ImmunotherapyVol. 75(4)
Okayama University (JP), Okayama University Hospital (JP), Kindai University (JP)
Good health and well-being
Openalex Percentile: Top 12%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer · Cancer Immunology Immunotherapy (2026) | TGRS Research Map | TGRS